Introgen`s p16 Cancer Therapeutic Receives Patent Introgen Owns Exclusive Worldwide License From The University of Texas System
...The patent covers the inhibition of tumor growth using the p16 tumor suppressor gene encoded in an adenoviral vector when delivered via...... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
Sep 05 7:30 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010905/daw017.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines